This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Rosen Law Firm Announces Investigation Of Securities Claims Against Galena Biopharma, Inc. – GALE

Stocks in this article: GALE

The Rosen Law Firm announces that it is investigating potential securities fraud claims against Galena Biopharma, Inc. (NASDAQ:GALE) resulting from allegations that GALE may have paid outsiders to pump its stock using false and misleading articles while insiders dumped their shares.

In July 2013, GALE entered into a contract with investor relations firm The DreamTeam Group (“DT”) to tout its stock for 240 days. DT itself then published a variety of articles, many if not all of which misleadingly omitted to disclose that DT was paid by GALE to promote it. Several of the articles were also falsely attributed to various third parties.

On January 26, 2014, Seeking Alpha, where some of DT’s articles were published, removed five DT-authored articles. Seeking Alpha claimed the articles violated its terms of use because they claimed that they were authored by three different anonymous authors, though they were in fact all written by DT. Then, on February 12, 2014, journalist Adam Feuerstein published an article on TheStreet.com revealing that GALE had paid for DT’s promotion. GALE’s stock price fell from $5.19 to $4.34, damaging investors. Then, on February 14, 2014, GALE issued a letter to its shareholders, in which it admitted that it had paid DT to promote it.

But in January 2014, before Mr. Feuerstein revealed that positive articles about GALE had been written in a paid promotional campaign, GALE CEO Mark J. Ahn sold net $2.79 million of GALE stock. Steven Kriegsman, a GALE Director who is also CEO of CytRX, another DT client, sold net $2.49 million of shares in January. Other insiders collectively sold net $4.7 million of shares.

The Rosen Law Firm is investigating a securities class action lawsuit on behalf of GALE investors. If you purchased GALE stock before February 12, 2014, please visit the website at http://rosenlegal.com for more information. You may also contact Jonathan Horne, Esq., or Phillip Kim, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at jhorne@rosenlegal.com or pkim@rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,612.14 -60.46 -0.34%
S&P 500 2,044.06 -7.76 -0.38%
NASDAQ 4,740.8110 -17.0680 -0.36%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs